Brief: AC Immune To Present Data From Phase II Crenezumab Alzheimer’s Prevention Initiative Study
02/08/2022 17:09
Aug 2 (Reuters) - AC Immune SA ACIU.O :
* DETAILED DATA FROM THE PHASE II CRENEZUMAB ALZHEIMER’S
PREVENTION INITIATIVE STUDY IN AUTOSOMAL DOMINANT ALZHEIMER’S
DISEASE PRESENTED AT AAIC
* AC IMMUNE SA - CRENEZUMAB WAS SAFE AND WELL TOLERATED WITH
NO
CASES OF ARIA-E OBSERVED DURING UP TO EIGHT-YEAR STUDY
Source text for Eikon: ID:nGNX1yh8Ds
Further company coverage: ACIU.O
((Reuters.Briefs@thomsonreuters.com;))
Recent news on AC Immune SA
See all newsBrief: Ac Immune To Receive Research Grant From Goradia Family For Development Of Aci-7104 In Parkinson’S Disease
AC Immune Q1 net loss narrows on lower expenses
Brief: AC Immune Announces Amendment To Morphomer ® Tau License And Collaboration Agreement With Lilly
U.S. STOCKS ON THE MOVE-Darden Restaurants, Mastercard, Accenture
U.S. STOCKS ON THE MOVE-Darden Restaurants, Mastercard, Accenture